Should you buy Viking Therapeutics stock now?
No, the technical signal for Viking Therapeutics is currently Strong Sell. Viking Therapeutics trades at $25.17 as of Oct 17, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -1.894 with falling momentum (signal: -1.406); RSI is at 35.9 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average). The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Viking Therapeutics stock?
There is currently no active analyst price target for Viking Therapeutics.
Is Viking Therapeutics a dividend stock?
No, Viking Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Viking Therapeutics stock?
Viking Therapeutics is rated as a stock in the risk category Speculative. the annual standard deviation is 68.1%, which classifies the stock as Speculative.
Is Viking Therapeutics overvalued?
Viking Therapeutics has the following valuation ratios: a P/B ratio of 11.9.
Is Viking Therapeutics overbought?
No, Viking Therapeutics is not overbought. RSI is at 35.9 (neutral zone). The technical indicators show: RSI is at 35.9 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 18.6% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Viking Therapeutics earnings report?
Viking Therapeutics reports its next earnings on October 28, 2026. The stock currently trades at $25.17.
Is Viking Therapeutics shorted?
Yes, Viking Therapeutics is shorted with 21.4% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Viking Therapeutics stock?
No, insiders are not buying Viking Therapeutics shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 3 sales. On a net basis, 6,268,442 $ worth of shares were sold. Across the last 20 reported transactions, the split is 2 purchases and 18 sales, with a net 31,113,137 $ sold. Active sellers include ZANTE GREG, Mancini Marianna, Lian Brian and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Viking Therapeutics a good stock?
Based on our total score, Viking Therapeutics is rated as a disastrous stock with a total score of 12 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 3/100, Quality: 6/100, Momentum: 29/100. Whether now is the time to buy is a separate question: the technical signal is Strong Sell. Whether Viking Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Viking Therapeutics stock?
The outlook for Viking Therapeutics based on current data: the stock is in a downtrend (below SMA50 and SMA200); the next earnings report is due on Oct 28, 2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Viking Therapeutics stock falling?
Viking Therapeutics is falling right now. The technical indicators show: the price is 18.6% below the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 21.4% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Viking Therapeutics go?
There is currently no active analyst price target for Viking Therapeutics. The stock has traded between $25.77 and $43.15 over the last 52 weeks. The price is 41.7% below the 52-week high, which can indicate potential if the underlying fundamentals are intact. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Viking Therapeutics fall?
The stock has traded as low as $25.77 over the last 52 weeks — that is 2.4% below the current price of $25.17. The biggest decline (drawdown) in the same period was 40.3% from high to low. Within a year, the price typically swings about ±68.1% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Viking Therapeutics do?
**What Viking Therapeutics does**
Viking Therapeutics (ticker: VKTX) is a company that develops new medicines for metabolic and hormone-related diseases. It does not sell products yet. Instead, it earns money by researching and testing drugs, with the goal of eventually bring... The company belongs to the Healthcare sector, more specifically the Biotechnology industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Viking Therapeutics as an investment.
Did Viking Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Viking Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Viking Therapeutics making money or losing money?
We have no current profitability data for Viking Therapeutics. See the latest report in the earnings history above.
Can Viking Therapeutics go bankrupt?
The bankruptcy risk of Viking Therapeutics is rated as elevated. Altman Z2 (a model for assessing financial distress) is -5.07 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 1 — which is weak. Debt relative to equity is 3% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Viking Therapeutics have a lot of debt?
No, Viking Therapeutics has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 3%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
